Sign in
WithdrawnNo phase

A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer

Key facts

Who runs it
Pfizer
Trial code
Status
Withdrawn
Started
16 May 2025
Ended
16 Aug 2025
Type of study
Observational
Treatments tested
  • Zirabev
Record updated
19 March 2025
Why it stopped
The study was withdrawn due to global supply chain issue. Zirabev was not launching in Korea.

Who can take part

Age
19 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Other criteria

  • Inclusion criteria; Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
  • Adults over 19 years old
  • Patients with non-small cell lung cancer, metastatic colorectal cancer, metastatic breast cancer, advanced or metastatic kidney cancer, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or glioblastoma multiforme
  • Patients eligible for Zirabev dosage based on local product document, local treatment guidelines and clinical judgment of the medical team
  • Evidence of a signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study; Exclusion criteria; Patients meeting any of the following criteria will not be included in the study:
  • Any patients (or a legally acceptable representative) who does not agree that Pfizer and companies working with Pfizer use his/her information
  • Patients for whom Zirabev is contraindicated according to the local product document

About the trial

What the trial wants to find out

This is a prospective, single-arm, open-label, non-interventional, multicenter, post-marketing surveillance to assess the safety and effectiveness of Zirabev(Bevacizumab biosimilar) in domestic patients with non-small cell lung cancer, metastatic colorectal cancer, metastatic breast cancer, advanced or metastatic kidney cancer, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or glioblastoma multiforme.

The group in the trial

  • Participants receiving Zirabev

    Treatment: Zirabev

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Single-arm, Open-label, Non-interventional, Multicenter, Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Non-small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Advanced or Metastatic Kidney Cancer, Cervical Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer or Glioblastoma Multiforme.
Record updated
19 March 2025